Why Motus GI Stock Is Skyrocketing Today

Motus GI Holdings Inc MOTS shares are trading higher after the company completed the first clinical evaluation of New Pure-Vu Gastro in upper gastrointestinal (GI) procedures to support FDA submission.

This initial clinical evaluation provided insight into the ability of the Pure-Vu Gen 4 Gastro device to navigate and evaluate the entire anatomy in the upper GI tract. 

The procedures in the upper GI tract were efficient for these first-time users, with the upper procedures averaging only 11 minutes. 

Similarly, in the colon, they were able to improve the average Boston Bowel Prep Scale (BBPS) in 9 patients from 5.9 before the use of Pure-Vu to 8.9 after the use of Pure-Vu with total procedure times averaging 24 minutes (the BBPS scale ranges from 0 (extremely dirty) to 9 (pristinely clean). 

Last week, Motus GI announced new clinical data showing a 33% hospital-wide improvement in incomplete bowel prep rate for colonoscopies during a 12-month study assessing the Pure-Vu EVS.

In January, Motus GI initiated a process to explore a range of strategic and financing alternatives and engaged Lake Street Capital Markets as an advisor.

Price Action: MOTS shares are up 48.60% at $1.07 on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPenny StocksHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!